Syniad’s Gemina Laboratories Announces a Successful Non-Brokered Private Placement

Vancouver, BC – March 19th, 2024 – Syniad Innovations Inc. (“Syniad”) is pleased to announce that Gemina Laboratories Ltd. (CSE: GLAB) (FRA:8I7), a developer of transformative chemistries for diagnostic tests, has raised gross proceeds of $910,000 under its non-brokered private placement of unsecured convertible notes of the Company.

Commenting on today’s announcement, Iain Evans, Syniad’s Chief Investment Officer, said: “It’s very pleasing to see Gemina announce a further injection of capital to advance its business, and we’re looking forward to seeing further progress in the year as the company goes from strength to strength.”

About Gemina Laboratories Ltd.

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19, influenza, and other viruses. Additional information on the Company can be found at www.geminalabs.com.